Direxion Daily Semiconductor Bull 3X Shares vs Zoetis Inc — how do they compare? Direxion Daily Semiconductor Bull 3X Shares trades at $125.61, while Zoetis Inc trades at $73.91 (market cap $30.40B). The key difference: Zoetis Inc pays a 2.88% dividend while Direxion Daily Semiconductor Bull 3X Shares pays none, and Direxion Daily Semiconductor Bull 3X Shares is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| SOXL | ZTS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $300.77 | $150.61 |
52-Week Low | $28.60 | $71.91 |
Market Cap | — | $30.40B |
Enterprise Value | — | $37.96B |
Dividend Yield | — | 2.88% |
Signals from Pluang's Aura AI — not financial advice
SOXL, the Direxion Daily Semiconductor Bull 3X ETF, gained 5.19% to $123.37, reflecting strong bullish momentum in semiconductor stocks. Technical indicators show a bullish overall signal with moving averages supporting upward momentum, while oscillators remain neutral. Recent news highlights ongoing institutional interest in semiconductor ETFs despite warnings about potential short-term volatility and tariff concerns from US trade policy discussions.
The outlook for SOXL remains tied to semiconductor sector performance, with AI demand providing long-term support. However, investors face significant risks from volatility decay inherent in leveraged ETFs, potential tariff impacts, and crowded trading positioning that could trigger sharp corrections. The ETF's performance is highly correlated with major semiconductor stocks like NVIDIA.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Trailing returns across standard periods
Latest headlines on both assets
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →